Latest filings (excl ownership)
8-K
Other Events
8 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
424B5
Prospectus supplement for primary offering
30 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Nov 23
424B5
Prospectus supplement for primary offering
29 Nov 23
8-K
Other Events
27 Nov 23
8-K
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
9 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
9 Aug 23
8-K
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
2 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Departure of Directors or Certain Officers
14 Mar 23
8-K
Other Events
8 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
1 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8 Nov 22
8-K
Other Events
7 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9 Aug 22
424B5
Prospectus supplement for primary offering
23 Jun 22
8-K
Other Events
23 Jun 22
424B5
Prospectus supplement for primary offering
22 Jun 22
8-K
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
21 Jun 22
S-8
Registration of securities for employees
2 Jun 22
8-K
Departure of Directors or Certain Officers
2 Jun 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
10 May 22
DEF 14A
Definitive proxy
28 Apr 22
8-K
Unregistered Sales of Equity Securities
22 Mar 22
8-K
Results of Operations and Financial Condition
10 Mar 22
424B5
Prospectus supplement for primary offering
1 Mar 22
8-K
Entry into a Material Definitive Agreement
1 Mar 22
Latest ownership filings
4
Seggern Christopher Von
12 Mar 24
4
SHERRY AULIN
12 Mar 24
4
CHRISTOPHER JOHN KENNEY
12 Mar 24
4
JAMES R. EMPFIELD
12 Mar 24
4
SHERRINGTON ROBIN
12 Mar 24
4
Andrea DiFabio
12 Mar 24
4
IAN MORTIMER
12 Mar 24
4
ELIZABETH A. GAROFALO
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
SHERRINGTON ROBIN
8 Mar 24
4
STEVEN GANNON
8 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
DRIEHAUS CAPITAL MANAGEMENT LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
4
SHERRINGTON ROBIN
2 Jan 24
4
MOHAMMAD AZAB
20 Dec 23
4/A
GARY PATOU
15 Dec 23
4
GARY PATOU
15 Dec 23
144
Notice of proposed sale of securities
14 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
4
Dawn Svoronos
24 Aug 23
144
Notice of proposed sale of securities
24 Aug 23
4
Justin D. Gover
10 Aug 23
3
Justin D. Gover
10 Aug 23
4
Gillian Cannon
10 Aug 23
3
Gillian Cannon
10 Aug 23
4
MOHAMMAD AZAB
2 Jun 23
4
GARY PATOU
2 Jun 23
4
STEVEN GANNON
2 Jun 23
4
Dawn Svoronos
2 Jun 23
4
ELIZABETH A. GAROFALO
2 Jun 23
4
SIMON N. PIMSTONE
2 Jun 23
4
Patrick Machado
2 Jun 23
4
SIMON N. PIMSTONE
1 Jun 23
144
Notice of proposed sale of securities
1 Jun 23
144
Notice of proposed sale of securities
31 May 23
144
Notice of proposed sale of securities
30 May 23